Great to be part of live pre-meeting #melanoma session w/ Dr. Mary Sue Brady on neoadjuvant therapy incl NeoACTIVATE trial #SSO2021 Society of Surgical Oncology AACR Stand Up To Cancer Mayo Clinic Comprehensive Cancer Center Mayo Clinic +"see" colleagues Sandra Wong Russell S. Berman MarkFariesMD Hidde Kroon Christina Angeles MD Michael Lowe

#SSO2021 Highly anticipated Presidential address from Dr. Howe today at 10:15 addressing the state of Society of Surgical Oncology and our collective efforts in combating cancer and the pandemic

#SSO2021 Upcoming John Wayne Lecture by Dr. Jatin Shah @sloan_kettering followed by American Cancer Society Lecture by Dr. Stacey Gabriel Broad Institute. Don't miss these two incredible thought leaders Society of Surgical Oncology

#SSO2021 Join me and Dr. Paul Dale Atrium Health for an excellent series of presentations on novel targets, prognostic factors and adjuvant systemic therapies in #melanoma and #merkelcellcarcinoma in the Melanoma parallel session Society of Surgical Oncology Winship Cancer Institute of Emory University

#SSO2021 Happening now: Management of high-risk melanoma session with Tina J Hieken MD Christina Angeles MD David Gyorki Cristina O’Donoghue Society of Surgical Oncology

Congrats to a great team led by Kristy Kummerow Broman Jonathan Zager, MD Active surveillance of patients who have sentinel node positive melanoma: An international, multi‐institution evaluation of adoption and early outcomes after MSLT‐2 acsjournals.onlinelibrary.wiley.com/doi/10.1002/cn…

Analysis of Head/Neck Melanoma Rx in post-MSLT 2 era from Dr. Baecher Winship Cancer Institute of Emory University and colleagues from 21 centers #EADO2021 Kristy Kummerow Broman Moffitt Cancer Center University of South Florida Tasha Hughes @umichsurgery Lesly A Dossett MD MPH James Sun, MD Michael Carr @sloan_kettering Melanoma Institute Australia Roger Olofsson Bagge

#WinshipClinicalTrial UCDCCSO034 | Biomarker Analysis of Neoadjuvant Intralesional Therapy in High-Risk Primary #Melanoma: A Multi-Institutional Phase II Study #melsm ➡️ fal.cn/3eVtV

#ASCO21 | Poster Session | Melanoma/Skin Cancers "Winship 4851-19: A pilot study of neoadjuvant and adjuvant cemiplimab for high-risk cutaneous squamous cell carcinoma" First Author: Michael Lowe, MD, MA (Michael Lowe) ➡️ fal.cn/3fRzT

In the latest episode of SurgOnc Today, Richard White, MD, moderates as Nasreen Vohra, MD, reviews updates on local therapies and Michael Lowe reviews updates on neoadjuvant trials in #melanoma. Listen at ow.ly/WV5450F3nv1 or subscribe on Apple Podcasts and Spotify.

Another significant step forward for MelMarT-II, with 23 more participants recruited last month. A fantastic global effort to improve outcomes for patients with stage II primary #melanoma. More info at masc.org.au/recruiting-tri… #clinicaltrials #surgery #cancerresearch

Winship and the Atlanta Braves have partnered to promote #sunsafety this summer. Winship surgical oncologist Michael Lowe will throw out the first pitch at the Braves game this Friday night and remind fans to play it safe in the sun. #EmoryBraves ⚾ emoryhealthcare.org/sunsafety

Perfect pitch Michael Lowe! Atlanta Braves Winship Cancer Institute of Emory University @EmoryHealthcare #SunSafety

Proud to represent Emory Healthcare Winship Cancer Institute of Emory University and Emory Surgery throwing out first pitch Atlanta Braves tonight.

Emory investigators will receive a total of $955,000 in funding for new research projects from the Morningside Center for Innovative and Affordable Medicine. The six awards include five team projects led by researchers from Winship. ➡️ fal.cn/3gHqf

SESC Sharks!

Excited to join my colleagues Tina J Hieken MD Ragini Kudchadkar, MD and Scott Albert in a thought provoking discussion.

Congratulations Sapna Patel and the S1801 study team on an incredible practice-changing effort Winship Cancer Institute of Emory University MD Anderson Cancer Center

Grateful for the tremendous efforts of the study team and our patients (and for the support of great colleagues like Christina Roland, MD, MS). What neoadjuvant regimen is the right one?! Winship Cancer Institute of Emory University

Results of SWOG Cancer Research Network S1801 in NEJM: Patients w resectable melanoma who got 3 doses of pembrolizumab before surgery & 15 doses after had significantly longer event-free survival than those who got 18 doses after surgery. nejm.org/doi/full/10.10… Sapna Patel MD Anderson Cancer Center .